Clinical trials: Cirrhosis Portal
Portal Hypertension, Cirrhosis, Liver
Perioperative Care of HVPG Measurement (CHESS1904): An International Multicenter Survey
Hepatic venous pressure gradient (HVPG) is an invasive test and requires technical skills of the operator and specialized instruments.
- Trial name
- NCT04121520
- Testing
- Questionnaire
- Where
- 10 sites in Brazil, China and 5 more
- Volunteers
- 200 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Chronic Liver Disease
An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis
Hepatic steatosis may cause inflammation and fibrosis within the liver potentially leading to end-stage liver disease cirrhosis, liver failure and death.
- Trial name
- FALL (NCT05335603)
- Where
- Denmark
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Cirrhosis, Erectile Dysfunction
Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis
The investigators want to analyze the effect of Vardenafil on Erectile Dysfunstion and portal hemodynamics in patients with liver cirrhosis.
- Trial name
- NCT02344823
- Testing
- Vardenafil, HVPG (Hepatic venous pressure measurement) baseline, HVPG (Hepatic venous pressure measurement) day 7
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Medical University of Vienna
Cirrhosis, Hepatic Encephalopathy
Effect of Brief Dietary Intervention on Ammonia Levels
Study the impact of differing meal contents on venous ammonia levels over time in patients with cirrhosis. Patients will be given specific meals and venous ammonia analyzed over time after those meals.
- Trial name
- NCT05376488
- Testing
- One meal
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
Cirrhosis
A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg
OPC-41061 will be orally administered at 7.5 mg/day for 7 days to cirrhosis patients with ascites despite having received conventional diuretic therapy.
- Trial name
- NCT01048788
- Testing
- OPC-41061
- Where
- 6 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Liver Cirrhosis, Ascites Hepatic
Fresh Frozen Plasma as a Substitute for Albumin in Patients Receiving a Large Volume Paracentesis
Large volume paracentesis with albumin administration is the standard of care for patients with refractory ascites complicating end-stage liver disease.
- Trial name
- NCT03202524
- Testing
- Fresh Frozen Plasma (FFP), Albumin
- Sponsor
- Montefiore Medical Center
Thrombocytopenia Related to Chronic Liver Disease, Anticoagulation Treatment
Safety of Anticoagulation Therapy in Cirrhotic Patients With PVT and Severe Thrombocytopenia
Severe thrombocytopenia (platelet count ≤ 50 × 10^9/L) can significantly increase the risk of bleeding. Safety of Anticoagulation (AC) therapy in cirrhotic patients with portal vein thrombosis (PVT) and severe thrombocytopenia is…
- Conditions
- Thrombocytopenia Related to Chronic Liver Disease, Anticoagulation Treatment, Safety, Portal Vein Thrombosis
- Trial name
- AC in PVT (NCT07885969)
- Testing
- Anticoagulation Therapy
- Where
- China
- Volunteers
- 304 people
- Sponsor
- Qilu Hospital of Shandong University
Liver Cirrhosis, Fibrosis
Growth Hormone in Decompensated Liver Cirrhosis
Globally, cirrhosis and liver cancer carries a huge burden and accounts for about 3.5% (2 million) of all deaths every year. Once decompensated, i.e.
- Conditions
- Liver Cirrhosis, Fibrosis, End Stage Liver Disease, Digestive System Disease
- Trial name
- NCT05253287
- Testing
- Growth Hormone
- Where
- India
- Volunteers
- 96 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Hepatic Pathology (Fibrosis, Cirrhosis, Porto Systemic Shunts)
Development of a Cognitive Tool for Rapid and Reliable Screening of Minimal Hepatic Encephalopathy: Pilot Study
The aim of this project is to evaluate the sensitivity and specificity of a cognitive test toward the presence of minimal hepatic encephalopathy (MHE).
- Trial name
- BLOCK-HE (NCT06619106)
- Testing
- Cognitive test
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatic Encephalopathy, Cirrhosis, Liver
HepQuant to Predict Hepatic Encephalopathy After TIPS
A pilot study to determine if a simple blood test can predict patients at risk for significant episodes of confusion and disorientation that can occur in patients who receive an artificial shunt through the liver to control…
- Trial name
- NCT04664621
- Testing
- HepQuant
- Where
- United States
- Sponsor
- Northwestern University
Cirrhosis, Portal Vein Thrombosis
The Effect of Rifaximin on Portal Vein Thrombosis
The aim of this study is to evaluate the efficacy of rifaximin in the treatment of portal vein thrombosis in cirrhotic patients
- Trial name
- ERPVT (NCT03631147)
- Testing
- Rifaximin
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatic Insufficiency
Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency
This clinical pharmacology research study will assess the safety and pharmacokinetics of the drug everolimus in patients with impaired hepatic function as compared to healthy volunteers.
- Trial name
- NCT00968591
- Testing
- Everolimus
- Where
- 3 sites in Germany, Russia and 1 more
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Alcoholic Liver Disease
Cognitive Function of Alcoholic Compensated Liver Cirrhosis
Differences in cognitive function between patients with viral and alcoholic compensated liver cirrhosis
- Trial name
- NCT04557774
- Testing
- Cognitive function test
- Where
- South Korea
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Chuncheon Sacred Heart Hospital
Cirrhosis, Liver Failure
Transfer Factor Efficacy in the Management of Cirrhosis-associated Immune Dysfunction
This study is aimed to assess the efficacy of Human derived Transfer factor ( T-lymphocytes homogenate that contains small molecular weight (10 kDa) molecules: various IFNs, ILs, chemokines, endorfins, heat shock proteins) in…
- Trial name
- IMUNO-HEGITO7 (NCT02837939)
- Testing
- Human derived Transfer factor, Aqua pro injectione 4ml ampules for subcutaneous injection
- Where
- Slovakia
- Sponsor
- Martin Janičko
Cirrhosis, Vascular Diseases
Endoscopic Ultrasound-Guided Portosystemic Pressure Gradient Measurements
Portal hypertension (PHT) is the main consequence of advanced chronic liver diseases (ACLD) and is often associated with severe complications leading to increased morbidity and mortality.
- Trial name
- EUSPREM (NCT06216509)
- Testing
- Endoscopic ultrasound pressure measurement
- Where
- Romania
- Volunteers
- 50 people
- Sponsor
- Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor
Hepatic Cirrhosis, Liver Fibrosis
A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis
This is a study of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis (NASH; the buildup of fat and inflammation in the liver that is not caused by alcohol) and liver cirrhosis (liver damage…
- Conditions
- Hepatic Cirrhosis, Liver Fibrosis, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis
- Trial name
- FALCON 2 (NCT03486912)
- Testing
- BMS-986036
- Where
- 91 sites in United States, Japan
- Volunteers
- 155 people
- Sponsor
- Bristol-Myers Squibb
Cirrhosis, Ascites Hepatic
Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT
The development of ascites is a landmark event in the natural history of cirrhosis and signifies a grim prognosis. Portal hypertension and splanchnic arterial vasodilatation are the major contributors in the development of…
- Trial name
- NCT05014594
- Testing
- Dapagliflozin (10Mg Tab) along with standard medical therapy
- Where
- India
- Volunteers
- 44 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Hepatic Encephalopathy, Cirrhosis
Early Diagnosis and Timely Treatment of Cirrhotic Patients With Minimal Hepatic Encephalopathy (CHESS-NCRCID 2106)
Hepatic encephalopathy (HE) is a common complication of cirrhosis, which seriously damages the life quality of patients. As the disease progresses, 50-80% of patients with cirrhosis develop HE.
- Trial name
- NCT05140837
- Testing
- Psychometric hepatic encephalopathy score & Stroop test, Drug therapy
- Where
- 31 sites in China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Liver Cirrhosis
Long-term Efficacy and Safety of LSD Versus TIPS for Cirrhotic Portal Hypertension Bleeding and Hypersplenism
This study aims to compare two treatments for cirrhotic portal hypertension with acute esophagogastric variceal bleeding and hypersplenism: laparoscopic splenectomy and azygoportal disconnection (LSD) and transjugular…
- Trial name
- LSD、TIPS (NCT07490405)
- Testing
- LSD, TIPS
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Northern Jiangsu People's Hospital
COVID-19, Chronic Liver Failure
Evaluation of Long Haul COVID-19 and Vaccine Immunogenicity in Patients With Liver Disease
The project is essential to understand the impact of the COVID-19 pandemic in patients with Chronic Liver Disease (CLD). The impact has been felt due to direct risk of COVID infection in self, or in caregivers, lack of access to…
- Conditions
- COVID-19, Chronic Liver Failure, Cirrhosis, Liver, Portal Hypertension
- Trial name
- EvaLongCovid (NCT05107271)
- Testing
- COVID-19 serosurvey
- Where
- India
- Volunteers
- 252 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh